Article: Enteropathy-associated T-cell lymphoma: Clinical and histological findings from the international peripheral T-Cell lymphoma project

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleEnteropathy-associated T-cell lymphoma: Clinical and histological findings from the international peripheral T-Cell lymphoma project
AuthorsDelabie, J9
Holte, H9
Vose, JM10
Ullrich, F10
Jaffe, ES1
Savage, KJ12
Connors, JM12
Rimsza, L13
Harris, NL2
MüllerHermelink, K8
Rüdiger, T5
Coiffier, B16
Gascoyne, RD12
Berger, F16
Tobinai, K7
Au, WY6
Liang, R6
Montserrat, E15
Hochberg, EP4
Pileri, S14
Federico, M3
Nathwani, B11
Armitage, JO10
Weisenburger, DD10
Issue Date2011
PublisherAmerican Society of Hematology. The Journal's web site is located at http://bloodjournal.hematologylibrary.org/
CitationBlood, 2011, v. 118 n. 1, p. 148-155 [How to Cite?]
DOI: http://dx.doi.org/10.1182/blood-2011-02-335216
AbstractFew large, international series of enteropathy-associated T-cell lymphoma (EATL) have been reported. We studied a cohort of 62 patients with EATL among 1153 patients with peripheral T-cell or natural killer (NK) - cell lymphoma from 22 centers worldwide. The diagnosis was made by a consensus panel of 4 expert hematopathologists using World Health Organization (WHO) criteria. Clinical correlations and survival analyses were performed. EATL comprised 5.4% of all lymphomas in the study and was most common in Europe (9.1%), followed by North America (5.8%) and Asia (1.9%). EATL type 1 was more common (66%) than type 2 (34%), and was especially frequent in Europe (79%). A clinical diagnosis of celiac sprue was made in 32.2% of the patients and was associated with both EATL type 1 and type 2. The median overall survival was only 10 months, and the median failure-free survival was only 6 months. The International Prognostic Index (IPI) was not as good a predictor of survival as the Prognostic Index for Peripheral T-Cell Lymphoma (PIT). Clinical sprue predicted for adverse survival independently of the PIT. Neither EATL subtype nor other biologic parameters accurately predicted survival. Our study confirms the poor prognosis of patients with EATL and the need for improved treatment options.
ISSN0006-4971
2011 Impact Factor: 9.898
2011 SCImago Journal Rankings: 1.698
DOIhttp://dx.doi.org/10.1182/blood-2011-02-335216
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorDelabie, J
dc.contributor.authorHolte, H
dc.contributor.authorVose, JM
dc.contributor.authorUllrich, F
dc.contributor.authorJaffe, ES
dc.contributor.authorSavage, KJ
dc.contributor.authorConnors, JM
dc.contributor.authorRimsza, L
dc.contributor.authorHarris, NL
dc.contributor.authorMüllerHermelink, K
dc.contributor.authorRüdiger, T
dc.contributor.authorCoiffier, B
dc.contributor.authorGascoyne, RD
dc.contributor.authorBerger, F
dc.contributor.authorTobinai, K
dc.contributor.authorAu, WY
dc.contributor.authorLiang, R
dc.contributor.authorMontserrat, E
dc.contributor.authorHochberg, EP
dc.contributor.authorPileri, S
dc.contributor.authorFederico, M
dc.contributor.authorNathwani, B
dc.contributor.authorArmitage, JO
dc.contributor.authorWeisenburger, DD
dc.date.accessioned2012-09-05T05:30:44Z
dc.date.available2012-09-05T05:30:44Z
dc.date.issued2011
dc.description.abstractFew large, international series of enteropathy-associated T-cell lymphoma (EATL) have been reported. We studied a cohort of 62 patients with EATL among 1153 patients with peripheral T-cell or natural killer (NK) - cell lymphoma from 22 centers worldwide. The diagnosis was made by a consensus panel of 4 expert hematopathologists using World Health Organization (WHO) criteria. Clinical correlations and survival analyses were performed. EATL comprised 5.4% of all lymphomas in the study and was most common in Europe (9.1%), followed by North America (5.8%) and Asia (1.9%). EATL type 1 was more common (66%) than type 2 (34%), and was especially frequent in Europe (79%). A clinical diagnosis of celiac sprue was made in 32.2% of the patients and was associated with both EATL type 1 and type 2. The median overall survival was only 10 months, and the median failure-free survival was only 6 months. The International Prognostic Index (IPI) was not as good a predictor of survival as the Prognostic Index for Peripheral T-Cell Lymphoma (PIT). Clinical sprue predicted for adverse survival independently of the PIT. Neither EATL subtype nor other biologic parameters accurately predicted survival. Our study confirms the poor prognosis of patients with EATL and the need for improved treatment options.
dc.description.natureLink_to_subscribed_fulltext
dc.identifier.citationBlood, 2011, v. 118 n. 1, p. 148-155 [How to Cite?]
DOI: http://dx.doi.org/10.1182/blood-2011-02-335216
dc.identifier.citeulike9564667
dc.identifier.doihttp://dx.doi.org/10.1182/blood-2011-02-335216
dc.identifier.epage155
dc.identifier.issn0006-4971
2011 Impact Factor: 9.898
2011 SCImago Journal Rankings: 1.698
dc.identifier.issue1
dc.identifier.pmid21566094
dc.identifier.scopuseid_2-s2.0-79960117770
dc.identifier.spage148
dc.identifier.urihttp://hdl.handle.net/10722/163384
dc.identifier.volume118
dc.languageeng
dc.publisherAmerican Society of Hematology. The Journal's web site is located at http://bloodjournal.hematologylibrary.org/
dc.publisher.placeUnited States
dc.relation.ispartofBlood
dc.relation.referencesReferences in Scopus
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 And Over
dc.subject.meshCeliac Disease - Classification - Mortality - Pathology
dc.subject.meshCohort Studies
dc.subject.meshConsensus
dc.subject.meshEnteropathy-Associated T-Cell Lymphoma - Classification - Mortality - Pathology
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshInternationality
dc.subject.meshKiller Cells, Natural - Pathology
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshPredictive Value Of Tests
dc.subject.meshPrognosis
dc.subject.meshSurvival Analysis
dc.subject.meshT-Lymphocytes - Pathology
dc.subject.meshWorld Health Organization
dc.titleEnteropathy-associated T-cell lymphoma: Clinical and histological findings from the international peripheral T-Cell lymphoma project
dc.typeArticle
Author Affiliations
  1. National Cancer Institute
  2. Massachusetts General Hospital
  3. Università degli Studi di Modena e Reggio Emilia
  4. Massachusetts General Hospital Cancer Center
  5. Städtischen Klinikum Karlsruhe
  6. The University of Hong Kong
  7. National Cancer Center Hospital
  8. Julius-Maximilians-Universität Würzburg
  9. Rikshospitalet-Radiumhospitalet HF
  10. University of Nebraska Medical Center
  11. Keck School of Medicine of USC
  12. British Columbia Cancer Agency
  13. University of Arizona
  14. Alma Mater Studiorum Università di Bologna
  15. Universitat de Barcelona
  16. Centre Hospitalier Lyon-Sud